Discordant genotypic resistance and HIV-1 genetic diversity from paired plasma and cerebrospinal fluid samples in Chinese settings

[1]  M. Peluso,et al.  Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load , 2012, AIDS.

[2]  Ning Li,et al.  An initial screening for HIV-associated neurocognitive disorders of HIV-1 infected patients in China , 2012, Journal of NeuroVirology.

[3]  Ning Li,et al.  Genetic analysis of HIV type 1 env gene in cerebrospinal fluid and plasma of infected Chinese paid blood donors. , 2012, AIDS research and human retroviruses.

[4]  Dexi Chen,et al.  Characterization of HIV type 1 env gene in cerebrospinal fluid and blood of infected Chinese patients. , 2011, AIDS research and human retroviruses.

[5]  M. Boivin,et al.  HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children , 2010, AIDS.

[6]  L. Varatharajan,et al.  Corrigendum to “The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research” [Antiviral Res. 82 (2) (2009) A99–A109] , 2009, Antiviral Research.

[7]  L. Varatharajan,et al.  The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research , 2009, Antiviral research.

[8]  Justin C McArthur,et al.  The prevalence and incidence of neurocognitive impairment in the HAART era , 2007, AIDS.

[9]  R. Price,et al.  Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. , 2006, The Journal of infectious diseases.

[10]  G. Ippolito,et al.  Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  L. Palmisano,et al.  The global status of resistance to antiretroviral drugs. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  C. Power,et al.  Human immunodeficiency virus type 1 genetic diversity in the nervous system: Evolutionary epiphenomenon or disease determinant? , 2005, Journal of NeuroVirology.

[13]  D. Richman,et al.  Genetic Composition of Human Immunodeficiency Virus Type 1 in Cerebrospinal Fluid and Blood without Treatment and during Failing Antiretroviral Therapy , 2005, Journal of Virology.

[14]  B. Brew,et al.  Independent Evolution of Human Immunodeficiency Virus (HIV) Drug Resistance Mutations in Diverse Areas of the Brain in HIV-Infected Patients, with and without Dementia, on Antiretroviral Treatment , 2004, Journal of Virology.

[15]  F. Clavel,et al.  HIV Drug Resistance , 2000, The New England journal of medicine.

[16]  Zhiwei Chen,et al.  HIV-1 subtype B’ dictates the AIDS epidemic among paid blood donors in the Henan and Hubei provinces of China , 2003, AIDS.

[17]  N. Sacktor,et al.  Human immunodeficiency virus-associated dementia: An evolving disease , 2003, Journal of NeuroVirology.

[18]  Y. Takebe,et al.  On-going generation of multiple forms of HIV-1 intersubtype recombinants in the Yunnan Province of China , 2002, AIDS.

[19]  V. Soriano,et al.  Higher efavirenz plasma levels correlate with development of insomnia. , 2001, Journal of acquired immune deficiency syndromes.

[20]  M. Zazzi,et al.  Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. , 2000, The Journal of infectious diseases.

[21]  A S Perelson,et al.  Drug concentration heterogeneity facilitates the evolution of drug resistance. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  F. Clavel,et al.  Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir. , 1997, AIDS.

[23]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[24]  K Bebenek,et al.  The accuracy of reverse transcriptase from HIV-1. , 1988, Science.

[25]  I. Grant,et al.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. , 2008, Archives of neurology.

[26]  J. Chen,et al.  Guidelines for diagnosis and treatment of HIV/AIDS in China (2005). , 2006, Chinese medical journal.